Traders should monitor the DENALI Part 2 topline data by year-end 2026 as a key catalyst; the current cash runway provides buffer, but future dilution risk remains if additional funding is needed post-2027.
Price Chart
Executive Summary
Zentalis Pharmaceuticals reported its 2025 financial results, highlighting a significant reduction in R&D and G&A expenses, with $245.9 million in cash providing a runway into late 2027. The company remains on track for key 2026 milestones, including dose confirmation in 1H 2026 and a topline readout from the DENALI Part 2 trial by year-end, which could support accelerated FDA approval of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, sufficient to fund operations into late 2027.
- R&D expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, driven by lower clinical, lab, manufacturing, and personnel costs.
- G&A expenses dropped to $37.7 million in 2025 from $87.1 million in 2024, largely due to a $47.1 million reduction in personnel expenses, including $40.8 million in non-cash stock-based compensation.
- No revenue was recorded in 2025, compared to $67.4 million in licensing revenue in 2024 from a prior collaboration.
- DENALI Part 2a enrollment completed; dose confirmation expected in 1H 2026, with topline data from Part 2 expected by end of 2026.
- ASPENOVA Phase 3 trial design aligned with FDA; initiation expected in 1H 2026.
Financial Impact
Operating expenses reduced by $105.8 million YoY, improving cash preservation. However, revenue dropped to $0 in 2025 from $67.4 million in 2024.
Risk Factors
- No revenue in 2025; future depends entirely on azenosertib's clinical and regulatory success.
- Prior revenue was non-recurring (licensing), making current business model unproven.
- Clinical trial delays or negative data could significantly impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.54 (+31.58%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.54 (+28.79%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.54 (−32.40%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.54 (−35.82%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.54 (−36.47%) |
Apr 17, 2026 23w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.54 (−45.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access